<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01519700</url>
  </required_header>
  <id_info>
    <org_study_id>EP06-302</org_study_id>
    <secondary_id>2010-024481-22</secondary_id>
    <nct_id>NCT01519700</nct_id>
  </id_info>
  <brief_title>Phase III Study Comparing the Efficacy and Safety of EP2006 and Filgrastim</brief_title>
  <acronym>PIONEER</acronym>
  <official_title>A Randomized, Double-blind, Parallel-group, Multi-center Phase III Study Comparing the Efficacy and Safety of EP2006 and Neupogen® in Breast Cancer Patients Treated With Myelosuppressive Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sandoz</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sandoz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will assess the efficacy of EP2006 compared to Filgrastim with respect to the mean
      duration of severe neutropenia during treatment with myelosuppressive chemotherapy in breast
      cancer patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy</measure>
    <time_frame>21 days (Cycle 1 of chemotherapy treatment)</time_frame>
    <description>Mean duration of severe neutropenia, defined as the mean number of consecutive days with Grade 4 neutropenia (ANC less than 0.5*10^9 cells/L)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Febrile Neutropenia</measure>
    <time_frame>21 weeks/ 6 cycles</time_frame>
    <description>Incidence of febrile neutropenia by duraton within each cycle and across all cycles. Febrile neutropenia is defined as oral temperature greater than or equal 38.3°C while having an Absolute Neutrophil Count &lt; 0.5*10^9 cells/L (both measured on the same day)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days of Fever</measure>
    <time_frame>21 weeks/ 6 cycles</time_frame>
    <description>Number of days of fever by cycle. Fever is defined as oral temperature greater than or equal to 38.3°C.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depth of Absolute Neutrophil Count Nadir</measure>
    <time_frame>Cycle 1/ 21 days</time_frame>
    <description>Depth of Absolute Neutrophil Count Nadir, defined as the patient's lowest Absolute Neutrophil Count in cycle 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Absolute Neutrophil Count Recovery</measure>
    <time_frame>Cycle 1/ 21 days</time_frame>
    <description>Time to Absolute Neutrophil Count recovery, defined as the time in days from Absolute Neutrophil Count nadir until the patient's Absolute Neutrophil Count increases to more or equal to 2*10^9 cells/L after the nadir in cycle 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Infections</measure>
    <time_frame>21 Weeks/ 6 cycles</time_frame>
    <description>Frequency of infections by cycle and across all cycles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Hospitalizations Due to Febrile Neutropenia</measure>
    <time_frame>21 Weeks/ 6 cycles</time_frame>
    <description>Incidence of hospitalizations due to Febrile Neutropenia</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">218</enrollment>
  <condition>Chemotherapy Associated Neutropenia</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>EP2006</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients will be teated with EP2006</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Filgrastim</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eligible patients will be teated with Filgrastim</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EP2006</intervention_name>
    <description>Eligible patients will be teated with EP2006</description>
    <arm_group_label>EP2006</arm_group_label>
    <other_name>Filgrastim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>Eligible patients will be teated with Filgrastim</description>
    <arm_group_label>Filgrastim</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with histologically proven breast cancer, eligible for neoadjuvant or
             adjuvant myelosuppressive chemotherapy

          2. Women ≥ 18 years of age

          3. Estimated life expectancy of more than six months

        Exclusion Criteria:

          1. Previous or concurrent malignancy except non-invasive non-melanoma skin cancer, in
             situ carcinoma of the cervix, or other solid tumor treated curatively, and without
             evidence of recurrence for at least ten years prior to study entry

          2. Any serious illness or medical condition that may interfere with safety, compliance,
             response to the products under investigation and their evaluation, e.g.:

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandoz</last_name>
    <role>Study Chair</role>
    <affiliation>Sandoz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Insitut Onkologie a Rehabilitaca na Plesi</name>
      <address>
        <city>Ves pod Plesi 110</city>
        <zip>26204</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem, III. Belgyogyaszati Klinika</name>
      <address>
        <city>Budapest</city>
        <zip>1125</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Onkoradiologia</name>
      <address>
        <city>Budapest</city>
        <zip>1145</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DE OEC, Onkologiai Tanszek</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Josa Andras Oktato Korhaz Nonprofit Kft</name>
      <address>
        <city>Nyiregyhaza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fejer Megyei Szent Gyorgy Korhaz, Onkologiai Osztaly</name>
      <address>
        <city>Szekesfehervar</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vas Megyei Markusovszky Korhaz, Onkoradiologiai Osztaly</name>
      <address>
        <city>Szombathely</city>
        <zip>9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daugavpils Regional Hospital</name>
      <address>
        <city>Daugavpils</city>
        <zip>5400</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institution of the Russian Academy of Medical Sciences Medical Radiology Research Center RAMS</name>
      <address>
        <city>Moscow</city>
        <state>Krasnogorsk district</state>
        <zip>143423</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution (SHI) &quot;Leningrad Regional Oncological Dispensary&quot; at the Surgery Department 2</name>
      <address>
        <city>Kuzmolovsky</city>
        <state>Leningrad region</state>
        <zip>188663</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Medical-Prophylactic Institution SMPI Reginal Clinical Oncological Dispensary</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution (SHI) &quot;Clinical Oncological Dispensary №1&quot; of Healthcare Department of Krasnodar Territory</name>
      <address>
        <city>Krasnodar</city>
        <zip>350040</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institution of the Russian Academy of Medical Sciences Russian Oncology Research Center n.a. N.N.Blochin of RAMS&quot;, Surgery Department of the Female Reproductive System Tumors</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affiliate No1 of State Healthcare Institution (SHI) &quot;Nizhny Novgorod Regional Oncological Dispensary&quot;</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603081</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institution of the Russian Academy of Medical Sciences Medical Radiology Research Center RAMS</name>
      <address>
        <city>Obninsk</city>
        <zip>249036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution SHI Pyatigorsk Oncological Dispensary</name>
      <address>
        <city>Pyatigorsk</city>
        <zip>357502</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Non-State Healthcare Institution NSHI</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>195271</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg State Healthcare Institution (SPb SHI) &quot;City Clinical Oncological Dispensary&quot;</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution (SHI)&quot;Voronezh Regional Clinical Oncological Dispensary&quot;</name>
      <address>
        <city>Voronezh</city>
        <zip>394000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultna nemocnica Nitra, Oddelenie radioterapie a klinickej onkologie</name>
      <address>
        <city>Nitra</city>
        <zip>95001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Communal Institution &quot;Krivorizhskiy oncology dispensary&quot; of Dnipropetrovsk regional Council, Chemotherapy Department</name>
      <address>
        <city>Kriviy Rig</city>
        <state>Dnipropetrovsk region</state>
        <zip>50048</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Communal Institution &quot;Dnipropetrovsk Сity multiple-discipline Clinical Hospital 4&quot; of Dnipropetrovsk Regional Council</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49102</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical center of Limited Liability Company &quot;Inter&quot;</name>
      <address>
        <city>Lugansk</city>
        <zip>91000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lviv state oncological regional treatment-and-diagnostics center, Chemotherapy Department</name>
      <address>
        <city>Lviv</city>
        <zip>79031</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Communal Institution &quot;Odesa regional clinical hospital&quot;, Mammology Center</name>
      <address>
        <city>Odesa</city>
        <zip>65025</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vinnytsya Regional Clinical Oncological Center, Chemotherapy Department</name>
      <address>
        <city>Vinnitsya</city>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Hungary</country>
    <country>Latvia</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Ukraine</country>
  </location_countries>
  <removed_countries>
    <country>Serbia</country>
  </removed_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2012</study_first_submitted>
  <study_first_submitted_qc>January 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2012</study_first_posted>
  <results_first_submitted>March 25, 2015</results_first_submitted>
  <results_first_submitted_qc>March 25, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 7, 2015</results_first_posted>
  <last_update_submitted>April 14, 2015</last_update_submitted>
  <last_update_submitted_qc>April 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Filgrastim</keyword>
  <keyword>G-CSF, neutropenia</keyword>
  <keyword>supportive care</keyword>
  <keyword>breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study population consisted of women of 18 years or older with histologically proven breast cancer who were eligible for neoadjuvant or adjuvant treatment with TAC chemotherapy. The study was aimed to randomize a total of 192 patients in approximately 65 centers worldwide.</recruitment_details>
      <pre_assignment_details>The study started with a screening period of up to 21 days. During the screening period, the eligibility of the patients to participate in the study was assessed based on safety evaluations. After completion of the screening period, the patients were randomized to either EP2006 or US-licensed Neupogen® in four groups (see below).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>EP2006</title>
          <description>Patients remained on EP2006 (their initial treatment) throughout the study daily dose of 5 mcg/kg body weight, subcutaneously</description>
        </group>
        <group group_id="P2">
          <title>EP2006 + Neupogen</title>
          <description>Patients received alternating treatment with EP2006 or Neupogen starting with the second cycle, daily dose of 5 mcg/kg body weight, subcutaneously</description>
        </group>
        <group group_id="P3">
          <title>Neupogen + EP2006</title>
          <description>Patients received alternating treatment with Neupogen or EP2006 starting with the 2nd cycle, daily dose of 5 mcg/kg body weight, subcutaneously</description>
        </group>
        <group group_id="P4">
          <title>Neupogen</title>
          <description>Patients remained on Neupogen (their initial treatment) throughout the study, daily dose of 5 mcg/kg body weight, subcutaneously</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="55"/>
                <participants group_id="P3" count="55"/>
                <participants group_id="P4" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated Cycle 1 EP2006</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="54"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated Cycle 1 Neupogen</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="55"/>
                <participants group_id="P4" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated Cycle 2 EP2006</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="55"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated Cycle 2 Neupogen</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated Cycle 3 EP2006</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated Cycle 3 Neupogen</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="54"/>
                <participants group_id="P4" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated Cycle 4 EP2006</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="50"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated Cycle 4 Neupogen</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated Cycle 5 EP2006</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated Cycle 5 Neupogen</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="48"/>
                <participants group_id="P4" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated Cycle 6 EP2006</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="48"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated Cycle 6 Neupogen</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="48"/>
                <participants group_id="P4" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reason</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The safety set consists of all patients who received at least one dose of study drug and had at least one post-baseline safety assessment</population>
      <group_list>
        <group group_id="B1">
          <title>EP2006</title>
          <description>Patients remained on EP2006 (their initial treatment) throughout the study</description>
        </group>
        <group group_id="B2">
          <title>EP2006 + Neupogen</title>
          <description>Patients received alternating treatment with EP2006 or Neupogen starting with the second cycle</description>
        </group>
        <group group_id="B3">
          <title>Neupogen + EP2006</title>
          <description>Patients received alternating treatment with Neupogen or EP2006 starting with the 2nd cycle</description>
        </group>
        <group group_id="B4">
          <title>Neupogen</title>
          <description>Patients remained on Neupogen (their initial treatment) throughout the study</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="53"/>
            <count group_id="B2" value="54"/>
            <count group_id="B3" value="55"/>
            <count group_id="B4" value="52"/>
            <count group_id="B5" value="214"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.5" spread="11.16"/>
                    <measurement group_id="B2" value="47.5" spread="11.64"/>
                    <measurement group_id="B3" value="49.7" spread="11.05"/>
                    <measurement group_id="B4" value="46.9" spread="10.91"/>
                    <measurement group_id="B5" value="48.9" spread="11.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="52"/>
                    <measurement group_id="B5" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy</title>
        <description>Mean duration of severe neutropenia, defined as the mean number of consecutive days with Grade 4 neutropenia (ANC less than 0.5*10^9 cells/L)</description>
        <time_frame>21 days (Cycle 1 of chemotherapy treatment)</time_frame>
        <population>PP population</population>
        <group_list>
          <group group_id="O1">
            <title>EP2006 + EP2006 &amp; Neupogen</title>
            <description>All subjects randomized to receive either EP2006 in Cycle 1</description>
          </group>
          <group group_id="O2">
            <title>Neupogen + Neupogen &amp; EP2006</title>
            <description>All subjects randomized to receive Neupogen in Cycle 1</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy</title>
          <description>Mean duration of severe neutropenia, defined as the mean number of consecutive days with Grade 4 neutropenia (ANC less than 0.5*10^9 cells/L)</description>
          <population>PP population</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.17" spread="1.11"/>
                    <measurement group_id="O2" value="1.2" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority limit: -1 day Power: 90% Confidence level: 97.5% Randomization ratio: 1:1 (EP2006:Neupogen)</non_inferiority_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.04</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>-0.26</ci_lower_limit>
            <estimate_desc>The one-sided 97.5% Confidence Interval: [-0.26, ∞).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Febrile Neutropenia</title>
        <description>Incidence of febrile neutropenia by duraton within each cycle and across all cycles. Febrile neutropenia is defined as oral temperature greater than or equal 38.3°C while having an Absolute Neutrophil Count &lt; 0.5*10^9 cells/L (both measured on the same day)</description>
        <time_frame>21 weeks/ 6 cycles</time_frame>
        <population>SAF-I (alternating safety) set: patients who received at least one dose of study medication after Cycle 1.</population>
        <group_list>
          <group group_id="O1">
            <title>EP2006</title>
            <description>Patients remained on EP2006 (their initial treatment) throughout the study</description>
          </group>
          <group group_id="O2">
            <title>EP2006 + Neupogen</title>
            <description>Patients received alternating treatment with EP2006 or Neupogen starting with the second cycle</description>
          </group>
          <group group_id="O3">
            <title>Neupogen + EP2006</title>
            <description>Patients received alternating treatment with Neupogen or EP2006 starting with the 2nd cycle</description>
          </group>
          <group group_id="O4">
            <title>Neupogen</title>
            <description>Patients remained on Neupogen (their initial treatment) throughout the study</description>
          </group>
          <group group_id="O5">
            <title>Total</title>
            <description>All patients</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Febrile Neutropenia</title>
          <description>Incidence of febrile neutropenia by duraton within each cycle and across all cycles. Febrile neutropenia is defined as oral temperature greater than or equal 38.3°C while having an Absolute Neutrophil Count &lt; 0.5*10^9 cells/L (both measured on the same day)</description>
          <population>SAF-I (alternating safety) set: patients who received at least one dose of study medication after Cycle 1.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1 - 0 Days duration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="54"/>
                    <measurement group_id="O4" value="51"/>
                    <measurement group_id="O5" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 - 1 Day duration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 - 2 Days duration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 - 0 Days duration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="55"/>
                    <measurement group_id="O4" value="51"/>
                    <measurement group_id="O5" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 - 1 Day duration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 - 0 Days duration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="54"/>
                    <measurement group_id="O4" value="51"/>
                    <measurement group_id="O5" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 - 0 Days duration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="50"/>
                    <measurement group_id="O4" value="50"/>
                    <measurement group_id="O5" value="202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 - 0 Days duration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="48"/>
                    <measurement group_id="O4" value="50"/>
                    <measurement group_id="O5" value="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 - 1 Day duration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 - 0 Days duration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="48"/>
                    <measurement group_id="O4" value="49"/>
                    <measurement group_id="O5" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 - 1 Day duration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Cycles - 0 Days duration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="54"/>
                    <measurement group_id="O4" value="51"/>
                    <measurement group_id="O5" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Cycles - 1 Day duration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Cycles - 2 Days duration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days of Fever</title>
        <description>Number of days of fever by cycle. Fever is defined as oral temperature greater than or equal to 38.3°C.</description>
        <time_frame>21 weeks/ 6 cycles</time_frame>
        <population>PP-I (alternating Per-Protocol) set: randomized patients who completed all six chemotherapy cycles without major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>EP2006</title>
            <description>Patients remained on EP2006 (their initial treatment) throughout the study</description>
          </group>
          <group group_id="O2">
            <title>EP2006 + Neupogen</title>
            <description>Patients received alternating treatment with EP2006 or Neupogen starting with the second cycle</description>
          </group>
          <group group_id="O3">
            <title>Neupogen + EP2006</title>
            <description>Patients received alternating treatment with Neupogen or EP2006 starting with the 2nd cycle</description>
          </group>
          <group group_id="O4">
            <title>Neupogen</title>
            <description>Patients remained on Neupogen (their initial treatment) throughout the study</description>
          </group>
          <group group_id="O5">
            <title>Total</title>
            <description>All patients</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days of Fever</title>
          <description>Number of days of fever by cycle. Fever is defined as oral temperature greater than or equal to 38.3°C.</description>
          <population>PP-I (alternating Per-Protocol) set: randomized patients who completed all six chemotherapy cycles without major protocol violations.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="46"/>
                <count group_id="O5" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1 - No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="46"/>
                    <measurement group_id="O5" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 - Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 - No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="44"/>
                    <measurement group_id="O4" value="46"/>
                    <measurement group_id="O5" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 - Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 - No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="44"/>
                    <measurement group_id="O4" value="45"/>
                    <measurement group_id="O5" value="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 - Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 - No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="43"/>
                    <measurement group_id="O4" value="46"/>
                    <measurement group_id="O5" value="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 - Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 - No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="43"/>
                    <measurement group_id="O4" value="45"/>
                    <measurement group_id="O5" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 - Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 - No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="44"/>
                    <measurement group_id="O4" value="46"/>
                    <measurement group_id="O5" value="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 - Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Depth of Absolute Neutrophil Count Nadir</title>
        <description>Depth of Absolute Neutrophil Count Nadir, defined as the patient's lowest Absolute Neutrophil Count in cycle 1</description>
        <time_frame>Cycle 1/ 21 days</time_frame>
        <population>FAS (full analysis) set: all patients who received at least one dose of study medication, analyzed according to randomization allocation</population>
        <group_list>
          <group group_id="O1">
            <title>EP2006 + EP2006 &amp; Neupogen</title>
            <description>All subjects randomized to receive either EP2006 in Cycle 1</description>
          </group>
          <group group_id="O2">
            <title>Neupogen + Neupogen &amp; EP2006</title>
            <description>All subjects randomized to receive Neupogen in Cycle 1</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All patients in Cycle 1</description>
          </group>
        </group_list>
        <measure>
          <title>Depth of Absolute Neutrophil Count Nadir</title>
          <description>Depth of Absolute Neutrophil Count Nadir, defined as the patient's lowest Absolute Neutrophil Count in cycle 1</description>
          <population>FAS (full analysis) set: all patients who received at least one dose of study medication, analyzed according to randomization allocation</population>
          <units>10^9 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.808" spread="1.3694"/>
                    <measurement group_id="O2" value="0.744" spread="1.2906"/>
                    <measurement group_id="O3" value="0.776" spread="1.3278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Absolute Neutrophil Count Recovery</title>
        <description>Time to Absolute Neutrophil Count recovery, defined as the time in days from Absolute Neutrophil Count nadir until the patient's Absolute Neutrophil Count increases to more or equal to 2*10^9 cells/L after the nadir in cycle 1</description>
        <time_frame>Cycle 1/ 21 days</time_frame>
        <population>FAS (full analysis) set: all patients who received at least one dose of study medication, analyzed according to randomization allocation. In the EP2006 + EP2006 &amp; Neupogen group, one patient’s time to Absolute Neutrophil Count recovery could not be measured as the nadir was the last measured timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>EP2006 + EP2006 &amp; Neupogen</title>
            <description>All subjects randomized to receive either EP2006 in Cycle 1</description>
          </group>
          <group group_id="O2">
            <title>Neupogen + Neupogen &amp; EP2006</title>
            <description>All subjects randomized to receive Neupogen in Cycle 1</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All patients in Cycle 1</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Absolute Neutrophil Count Recovery</title>
          <description>Time to Absolute Neutrophil Count recovery, defined as the time in days from Absolute Neutrophil Count nadir until the patient's Absolute Neutrophil Count increases to more or equal to 2*10^9 cells/L after the nadir in cycle 1</description>
          <population>FAS (full analysis) set: all patients who received at least one dose of study medication, analyzed according to randomization allocation. In the EP2006 + EP2006 &amp; Neupogen group, one patient’s time to Absolute Neutrophil Count recovery could not be measured as the nadir was the last measured timepoint.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="0" upper_limit="6"/>
                    <measurement group_id="O2" value="2.0" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O3" value="2.0" lower_limit="0" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Infections</title>
        <description>Frequency of infections by cycle and across all cycles</description>
        <time_frame>21 Weeks/ 6 cycles</time_frame>
        <population>SAF-I (alternating safety) set: patients who received at least one dose of study medication after Cycle 1. Comparison made for alternating versus non-alternating treatment groups.</population>
        <group_list>
          <group group_id="O1">
            <title>EP2006 + Neupogen</title>
            <description>All subjects randomized to receive either EP2006 or Neupogen.</description>
          </group>
          <group group_id="O2">
            <title>EP2006 &amp; Neupogen + Neupogen &amp; EP2006</title>
            <description>All subjects randomized to receive EP2006 &amp; Neupogen + Neupogen &amp; EP2006.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All patients in Cycle 1</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Infections</title>
          <description>Frequency of infections by cycle and across all cycles</description>
          <population>SAF-I (alternating safety) set: patients who received at least one dose of study medication after Cycle 1. Comparison made for alternating versus non-alternating treatment groups.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1 - No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="104"/>
                    <measurement group_id="O3" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 - Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 - No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="102"/>
                    <measurement group_id="O3" value="202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 - Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 - No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="107"/>
                    <measurement group_id="O3" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 - Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 - No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="104"/>
                    <measurement group_id="O3" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 - Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 - No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="106"/>
                    <measurement group_id="O3" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 - Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 - No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="106"/>
                    <measurement group_id="O3" value="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 - Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Cycles - No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="97"/>
                    <measurement group_id="O3" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Cycles - Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Hospitalizations Due to Febrile Neutropenia</title>
        <description>Incidence of hospitalizations due to Febrile Neutropenia</description>
        <time_frame>21 Weeks/ 6 cycles</time_frame>
        <population>SAF-I (alternating safety) set: patients who received at least one dose of study medication after Cycle 1.</population>
        <group_list>
          <group group_id="O1">
            <title>EP2006</title>
            <description>Patients remained on EP2006 (their initial treatment) throughout the study</description>
          </group>
          <group group_id="O2">
            <title>EP2006 + Neupogen</title>
            <description>Patients received alternating treatment with EP2006 or Neupogen starting with the second cycle</description>
          </group>
          <group group_id="O3">
            <title>Neupogen + EP2006</title>
            <description>Patients received alternating treatment with Neupogen or EP2006 starting with the 2nd cycle</description>
          </group>
          <group group_id="O4">
            <title>Neupogen</title>
            <description>Patients remained on Neupogen (their initial treatment) throughout the study</description>
          </group>
          <group group_id="O5">
            <title>Total</title>
            <description>All patients</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Hospitalizations Due to Febrile Neutropenia</title>
          <description>Incidence of hospitalizations due to Febrile Neutropenia</description>
          <population>SAF-I (alternating safety) set: patients who received at least one dose of study medication after Cycle 1.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="55"/>
                    <measurement group_id="O4" value="51"/>
                    <measurement group_id="O5" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>EP2006</title>
          <description>Patients remained on EP2006 (their initial treatment) throughout the study</description>
        </group>
        <group group_id="E2">
          <title>EP2006 + Neupogen</title>
          <description>Patients received alternating treatment with EP2006 or Neupogen starting with the second cycle</description>
        </group>
        <group group_id="E3">
          <title>Neupogen + EP2006</title>
          <description>Patients received alternating treatment with Neupogen or EP2006 starting with the 2nd cycle</description>
        </group>
        <group group_id="E4">
          <title>Neupogen</title>
          <description>Patients remained on Neupogen (their initial treatment) throughout the study</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="50" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E2" events="18" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E3" events="20" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E4" events="22" subjects_affected="6" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="53"/>
                <counts group_id="E2" events="9" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E4" events="24" subjects_affected="11" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Leucopenia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E2" events="12" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E4" events="9" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="103" subjects_affected="29" subjects_at_risk="53"/>
                <counts group_id="E2" events="95" subjects_affected="33" subjects_at_risk="54"/>
                <counts group_id="E3" events="116" subjects_affected="32" subjects_at_risk="55"/>
                <counts group_id="E4" events="149" subjects_affected="37" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="54"/>
                <counts group_id="E3" events="21" subjects_affected="13" subjects_at_risk="55"/>
                <counts group_id="E4" events="11" subjects_affected="8" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="27" subjects_affected="9" subjects_at_risk="53"/>
                <counts group_id="E2" events="22" subjects_affected="10" subjects_at_risk="54"/>
                <counts group_id="E3" events="21" subjects_affected="10" subjects_at_risk="55"/>
                <counts group_id="E4" events="19" subjects_affected="9" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" events="10" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" events="7" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E4" events="6" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" events="4" subjects_affected="2" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="66" subjects_affected="20" subjects_at_risk="53"/>
                <counts group_id="E2" events="98" subjects_affected="28" subjects_at_risk="54"/>
                <counts group_id="E3" events="111" subjects_affected="32" subjects_at_risk="55"/>
                <counts group_id="E4" events="101" subjects_affected="28" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="52" subjects_affected="17" subjects_at_risk="53"/>
                <counts group_id="E2" events="17" subjects_affected="9" subjects_at_risk="54"/>
                <counts group_id="E3" events="38" subjects_affected="11" subjects_at_risk="55"/>
                <counts group_id="E4" events="38" subjects_affected="13" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" events="14" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="53"/>
                <counts group_id="E2" events="8" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" events="21" subjects_affected="8" subjects_at_risk="53"/>
                <counts group_id="E2" events="8" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E3" events="6" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E4" events="32" subjects_affected="13" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="33" subjects_affected="13" subjects_at_risk="53"/>
                <counts group_id="E2" events="46" subjects_affected="20" subjects_at_risk="54"/>
                <counts group_id="E3" events="60" subjects_affected="19" subjects_at_risk="55"/>
                <counts group_id="E4" events="60" subjects_affected="19" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Musculosceletal pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="8" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Periferal sensory neur.</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="43" subjects_affected="41" subjects_at_risk="53"/>
                <counts group_id="E2" events="45" subjects_affected="44" subjects_at_risk="54"/>
                <counts group_id="E3" events="46" subjects_affected="43" subjects_at_risk="55"/>
                <counts group_id="E4" events="44" subjects_affected="43" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="15" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" events="19" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E4" events="23" subjects_affected="6" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="10" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" events="7" subjects_affected="2" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI shall provide Sponsor with any presentation at least 15 working days prior to disclosure and any other publication at least 45 working days prior to disclosure. Sponsor may require amendments on reasonable grounds: (a) accuracy of publication; (b) confidentiality of proprietary information; (c) intellectual property protection; (d) to enable further information to be provided. Sponsor may require publications or presentations to be delayed up to four (4) months to enable patent application.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Roumen Nakov, Global Programme Medical Director</name_or_title>
      <organization>Sandoz</organization>
      <phone>+49 8024 4764704</phone>
      <email>roumen.nakov@sandoz.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

